These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 31829441)

  • 1. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
    Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
    J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.
    León-Castillo A; Gilvazquez E; Nout R; Smit VT; McAlpine JN; McConechy M; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Soslow RA; Ganesan R; Matias-Guiu X; Oliva E; Harrison BT; Church DN; Gilks CB; Bosse T
    J Pathol; 2020 Mar; 250(3):312-322. PubMed ID: 31829447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas.
    Matsumoto N; Manrai P; Rottmann D; Wu X; Assem H; Hui P; Buza N
    Int J Gynecol Pathol; 2023 Nov; 42(6):567-575. PubMed ID: 36730675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.
    Köbel M; Kang EY
    Int J Gynecol Pathol; 2021 Jan; 40(1):32-40. PubMed ID: 33290354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.
    Vermij L; Léon-Castillo A; Singh N; Powell ME; Edmondson RJ; Genestie C; Khaw P; Pyman J; McLachlin CM; Ghatage P; de Boer SM; Nijman HW; Smit VTHBM; Crosbie EJ; Leary A; Creutzberg CL; Horeweg N; Bosse T;
    Mod Pathol; 2022 Oct; 35(10):1475-1483. PubMed ID: 35752743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subclonal p53 immunostaining in the diagnosis of endometrial carcinoma molecular subtype.
    Huvila J; Thompson EF; Vanden Broek J; Lum A; Senz J; Leung S; Gilks CB; Köbel M; McAlpine JN; Jamieson A
    Histopathology; 2023 Dec; 83(6):880-890. PubMed ID: 37580913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.
    Schultheis AM; Martelotto LG; De Filippo MR; Piscuglio S; Ng CK; Hussein YR; Reis-Filho JS; Soslow RA; Weigelt B
    Int J Gynecol Pathol; 2016 Jul; 35(4):289-300. PubMed ID: 26556035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
    Brett MA; Atenafu EG; Singh N; Ghatage P; Clarke BA; Nelson GS; Bernardini MQ; Köbel M
    Int J Gynecol Pathol; 2021 Mar; 40(2):116-123. PubMed ID: 32265358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.
    Rios-Doria E; Momeni-Boroujeni A; Friedman CF; Selenica P; Zhou Q; Wu M; Marra A; Leitao MM; Iasonos A; Alektiar KM; Sonoda Y; Makker V; Jewell E; Liu Y; Chi D; Zamarin D; Abu-Rustum NR; Aghajanian C; Mueller JJ; Ellenson LH; Weigelt B
    Gynecol Oncol; 2023 Jul; 174():262-272. PubMed ID: 37245486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpretation of somatic POLE mutations in endometrial carcinoma.
    León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
    J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Surface epithelial slackening" pattern in endometrioid carcinoma: A morphological feature for differentiating the POLE mutation-subtype from the no specific molecular profile subtype.
    Kitazono I; Akahane T; Yokoyama S; Kobayashi Y; Togami S; Yanazume S; Tasaki T; Noguchi H; Tabata K; Kobayashi H; Tanimoto A
    Pathol Res Pract; 2023 Jul; 247():154563. PubMed ID: 37229919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized p53 immunohistochemistry is an accurate predictor of
    Köbel M; Piskorz AM; Lee S; Lui S; LePage C; Marass F; Rosenfeld N; Mes Masson AM; Brenton JD
    J Pathol Clin Res; 2016 Oct; 2(4):247-258. PubMed ID: 27840695
    [No Abstract]   [Full Text] [Related]  

  • 14. Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population.
    Kang N; Zhang X; Wang Z; Dai Y; Lu S; Su W; Gai F; Zhu C; Shen D; Wang J
    Pathol Res Pract; 2024 Feb; 254():155152. PubMed ID: 38277742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
    Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
    Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.
    Talhouk A; Jamieson A; Crosbie EJ; Taylor A; Chiu D; Leung S; Grube M; Kommoss S; Gilks CB; McAlpine JN; Singh N
    Int J Gynecol Pathol; 2023 Jul; 42(4):353-363. PubMed ID: 36731023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?
    Sakamoto I; Kagami K; Nozaki T; Hirotsu Y; Amemiya K; Oyama T; Omata M
    Am J Surg Pathol; 2023 Oct; 47(10):1144-1150. PubMed ID: 37528644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification.
    Thompson EF; Huvila J; Jamieson A; Leung S; Lum A; Offman S; Lytwyn A; Sur ML; Hoang L; Irving J; van der Westhuizen N; Morin C; Bicamumpaka C; Azordegan N; Gougeon F; Ennour-Idrissi K; Senz J; McConechy MK; Aguirre-Hernandez R; Lui V; Kuo C; Bell C; Salisbury T; Lawson J; He E; Wang S; Chiu D; Kean S; Samouëlian V; Salvador S; Gotlieb W; Helpman L; Scott S; Wohlmuth C; Vicus D; Plante M; Talhouk A; Huntsman D; Parra-Herran C; Kinloch M; Grondin K; Gilks CB; McAlpine JN;
    Mod Pathol; 2022 Dec; 35(12):1974-1982. PubMed ID: 36241860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.
    Yu S; Sun Z; Zong L; Yan J; Yu M; Chen J; Lu Z
    J Gynecol Oncol; 2022 May; 33(3):e38. PubMed ID: 35320887
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Na K; Sung JY; Kim HS
    Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.